The short version of counterion fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
=== Appeal === Claus von Bülow hired Harvard law professor Alan Dershowitz for his appeal. Dershowitz's campaign to acquit him was assisted by the then-Harvard Law School student and later television personality Jim Cramer; Cramer felt then and later wrote publicly that von Bülow was "supremely guilty" of the crime. Dershowitz and his other attorneys produced evidence of Sunny von Bülow's excessive drug use, including testimony by both Truman Capote and Joanne Carson (second wife of Johnny Carson) and more than ten of Sunny's friends. Some of the expert witness testimony was excluded as hypothetical or hearsay. Additional expert witness testimony cast doubt on the validity of evidence that a syringe contained traces of insulin. The appeals court quashed the conviction on several grounds, including the appellate court's ruling that justice for the accused should override attorney–client privilege; and that therefore the notes taken by Kuh, the Auersperg children's attorney, should be disclosed. These notes called into question the credibility of her maid, Ms. Schrallhammer, who had been a key witness for the prosecution. At the second trial the defense called nine medical experts, all world-renowned university professors, who testified that the two comas were not caused by insulin, but by a combination of ingested (not injected) drugs, alcohol, and her chronic health conditions. The experts were John Caronna (vice chairman of neurology, Cornell); Leo Dal Cortivo (former president, U.S.
=== Adults === The World Health Organization recommends a minimal acceptable intake of approximately 1.3 mg/day. These values are considered to be adequate and safe for most of the general population. In North America, the U.S. Institute of Medicine (IOM) set the Recommended Dietary Allowance (RDA) for copper for healthy adult men and women at 0.9 mg/day. As for safety, the IOM also sets Tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of copper, the UL is set at 10 mg/day. The European Food Safety Authority reviewed the same safety question and set its UL at 5 mg/day.
As of November 2024, there are 17 supermarket chains currently operating in the United Kingdom. The food retail market has been dominated by the 'big four' supermarkets – Tesco, Sainsbury's, Asda and Morrisons – which made up more than three quarters of sector market share in 2010. Tesco is the largest retailer in Great Britain, with a market share of 28.5% at the start of 2025. However, discounters Lidl and Aldi have grown rapidly. A number of sources reported that in September 2022, Aldi overtook Morrisons to become Great Britain's fourth largest grocery retailer. At the end of 2022, Morrisons and Aldi both remained at 9.1%. Collectively, the big four accounted for two thirds and the big four and discounters combined for five sixths of the grocery market share at the start of 2025. Northern Ireland has similar major chains. In 2022, Tesco was the largest retailer in NI, followed by Sainsbury's, Asda and Lidl. However, the market is different because some chains are not shared between the different parts of the UK. For example, Aldi and Morrisons do not operate there.
== Artificial enzymes == New approaches to design artificial enzymes based on amino acids or peptides as characteristic molecular moieties have led to a significant expansion of the field of artificial enzymes or enzyme mimics. Recent results by the group of Rob Liskamp have shown that scaffolded histidine residues can be used as mimics of certain metalloproteins and -enzymes. The structural mimicry of certain copper proteins (e.g. hemocyanin, tyrosinase and catechol oxidase), containing type-3 copper binding sites, has been shown. This is a significant improvement since the use of scaffolded histidine residues is one step closer to the mimicry of enzymes by biologically relevant species.
Sources: en.wikipedia.org
In modern terminology, Malay remains the name of an ethnoreligious group of Austronesian people predominantly inhabiting the Malay Peninsula and portions of the adjacent islands of Southeast Asia, including the east coast of Sumatra, the coast of Borneo, and smaller islands that lie between these areas. The state that gained independence from the United Kingdom in 1957 took the name the Federation of Malaya, chosen in preference to other potential names such as Malaysia and Langkasuka, after the historic kingdom located at the upper section of the Malay Peninsula in the first millennium CE. In 1963, the name Malaysia was adopted when the existing states of the Federation of Malaya, plus Singapore, North Borneo, and Sarawak, formed a new federation. One theory posits the name was chosen so that si represented the inclusion of Singapore, North Borneo, and Sarawak. Politicians in the Philippines contemplated renaming their state Malaysia before the modern country took the name.
Dopamine β-hydroxylase (DBH), also known as dopamine β-monooxygenase, is an enzyme (EC 1.14.17.1) that in humans is encoded by the DBH gene. Dopamine β-hydroxylase catalyzes the conversion of dopamine to norepinephrine.
== Management == Treatment is by medication and/or surgery. Medication consists mainly of acetylcholinesterase inhibitors to directly improve muscle function and immunosuppressant drugs to reduce the autoimmune process. Thymectomy is a surgical method to treat MG especially in younger patients and those with a thymoma.
Sources: en.wikipedia.org
=== Cardiovascular disease === Adult exposure to PAHs has been linked to cardiovascular disease. PAHs are among the complex suite of contaminants in tobacco smoke and particulate air pollution and may contribute to cardiovascular disease resulting from such exposures. In laboratory experiments, animals exposed to certain PAHs have shown increased development of plaques (atherogenesis) within arteries. Potential mechanisms for the pathogenesis and development of atherosclerotic plaques may be similar to the mechanisms involved in the carcinogenic and mutagenic properties of PAHs. A leading hypothesis is that PAHs may activate the cytochrome enzyme CYP1B1 in vascular smooth muscle cells. This enzyme then metabolically processes the PAHs to quinone metabolites that bind to DNA in reactive adducts that remove purine bases. The resulting mutations may contribute to unregulated growth of vascular smooth muscle cells or to their migration to the inside of the artery, which are steps in plaque formation. These quinone metabolites also generate reactive oxygen species that may alter the activity of genes that affect plaque formation. Oxidative stress following PAH exposure could also result in cardiovascular disease by causing inflammation, which has been recognized as an important factor in the development of atherosclerosis and cardiovascular disease.
== Research == Leptin is currently being evaluated as a potential target for the treatment of anorexia nervosa. It is hypothesized that the gradual loss of body fat mass, and more specifically the ensuing low leptin levels, escalate the preexisting drive for thinness into an obsessive-compulsive-like and addictive-like state. It was shown that short-term metreleptin treatment of patients with anorexia nervosa had rapid on-set of beneficial cognitive, emotional, and behavioral effects. Among other things, depression, drive for activity, repetitive thoughts of food, inner restlessness, and weight phobia decreased rapidly. Whether metreleptin (or another leptin analogue) is a suitable treatment for anorexia nervosa is currently unknown. Potential side effects are weight loss and the development of anti-metreleptin antibodies.
costs in 2016 were substantially higher than other OECD countries, at 17.2% GDP versus 12.4% GDP for the next most expensive country (Switzerland). For scale, a 5% GDP difference represents about $1 trillion or $3,000 per person. Some of the many reasons cited for the cost differential with other countries include: Higher administrative costs of a private system with multiple payment processes; higher costs for the same products and services; more expensive volume/mix of services with higher usage of more expensive specialists; aggressive treatment of very sick elderly versus palliative care; less use of government intervention in pricing; and higher income levels driving greater demand for healthcare. Healthcare costs are a fundamental driver of health insurance costs, which leads to coverage affordability challenges for millions of families. There is ongoing debate whether the current law (ACA/Obamacare) and the Republican alternatives (AHCA and BCRA) do enough to address the cost challenge.
Native enteropeptidase and the isolated light chain have similar activity toward Gly-(Asp)4-Lys-NHNap, but the secluded light chain has distinctly decreased activity toward trypsinogen . An analogous selective defect in the recognition of trypsinogen can be produced in two-chain enteropeptidase by heating or by acetylation. This behavior implies that the catalytic center and one or more secondary substrate-binding sites are essential for optimal recognition of trypsinogen.
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.